Skip to main content

Telephone Genetic Counseling Intervention in Enhancing Genetic Cancer Risk Assessment in Latinas at Risk of Hereditary Breast and Ovarian Cancer

Trial Status: Active

This phase II trial studies how well a telephone genetic counseling intervention works in enhancing genetic cancer risk assessment in Latinas at risk of hereditary breast and ovarian cancer. Genetic counseling may help providers and patients make decisions for cancer prevention or cancer treatment. Adapting a telephone genetic counseling intervention in Spanish for Latinas who are at risk of hereditary breast and ovarian cancer may enhance their use of genetic counseling services.

Inclusion Criteria

  • Self-identify as Latino/Hispanic
  • Diagnosed with breast cancer
  • At high risk of carrying a hereditary breast and ovarian cancer (HBOC) mutation based on the National Comprehensive Cancer Network

Exclusion Criteria

  • Not speaking Spanish and not having the cognitive ability to provide informed consent

District of Columbia

Washington
MedStar Georgetown University Hospital
Status: ACTIVE
Contact: Alejandra Hurtado de Mendoza
Phone: 202-687-8916

PRIMARY OBJECTIVES:

I. To culturally adapt the telephone genetic counseling intervention for Latina women at-risk of hereditary breast and ovarian cancer.

SECONDARY OBJECTIVES:

I. Explore communication patterns in 20 telephone genetic counseling (TGC) and genetic counseling sessions with an interpreter using quantitative and qualitative methods.

OUTLINE:

Patients receive educational material consisting of information about the genetic counseling sessions. Patients then participate in a telephone genetic counseling session over 90 minutes. Patients may also undergo collection of saliva for genetic testing after first genetic counseling session. Patients who undergo collection of saliva then participate in a second telephone genetic counseling session over 30 minutes to discuss the test results.

After completion of study, patients are followed up at 3 months.

Trial Phase Phase II

Trial Type Prevention

Lead Organization
MedStar Georgetown University Hospital

Principal Investigator
Alejandra Hurtado de Mendoza

  • Primary ID 2017-0566
  • Secondary IDs NCI-2019-01066
  • Clinicaltrials.gov ID NCT03959267